Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma

In this study we assessed the usefulness of serum Transforming Growth Factor-beta1 (TGF-beta1) and soluble Fas (sFas) in distinguishing liver cirrhosis (LC) with and without hepatocellular carcinoma (HCC) as compared with alpha-fetoprotein (AFP). Serum TGF-beta1 and sFas levels were measured by ELIS...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2000-06, Vol.12 (6), p.811-814
Main Authors: Sacco, R, Leuci, D, Tortorella, C, Fiore, G, Marinosci, F, Schiraldi, O, Antonaci, S
Format: Article
Language:English
Subjects:
Adult
Aged
alpha-Fetoproteins - analysis
Biomarkers, Tumor - blood
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - complications
Carcinoma, Hepatocellular - immunology
fas Receptor - blood
Female
Humans
Liver Cirrhosis - blood
Liver Cirrhosis - etiology
Liver Cirrhosis - immunology
Liver Neoplasms - blood
Liver Neoplasms - complications
Liver Neoplasms - immunology
Male
Middle Aged
Regression Analysis
Transforming Growth Factor beta - blood
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study we assessed the usefulness of serum Transforming Growth Factor-beta1 (TGF-beta1) and soluble Fas (sFas) in distinguishing liver cirrhosis (LC) with and without hepatocellular carcinoma (HCC) as compared with alpha-fetoprotein (AFP). Serum TGF-beta1 and sFas levels were measured by ELISA in 51 LC patients, 54 patients with HCC and 30 healthy donors. Considering as a cut-off limit (mean+1SD of controls) 74 pg/ml and 637 pg/ml for TGF-beta1 and sFas, respectively, we computed serum concentrations of TGF-beta1 and sFas as a score (mean+/-SD). The positive frequency of serum TGF-beta1 levels in HCC patients (54%) was greater than in LC patients (26%) and healthy donors (3%). TGF-beta1 levels were higher in HCC (1.6+/-0.5) than in LC (1.1+/-0.2) (P
ISSN:1043-4666